首页> 美国卫生研究院文献>Scientific Reports >Utility Of POC Xpert HIV-1 Tests For Detection-Quantification Of Complex HIV Recombinants Using Dried Blood Spots From Kinshasa D. R. Congo
【2h】

Utility Of POC Xpert HIV-1 Tests For Detection-Quantification Of Complex HIV Recombinants Using Dried Blood Spots From Kinshasa D. R. Congo

机译:使用来自刚果民主共和国金沙萨的干血斑的POC Xpert HIV-1检测工具检测复杂的HIV重组子的定量方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Point-of-Care (POC) molecular assays improve HIV infant diagnosis and viral load (VL) quantification in resource-limited settings. We evaluated POC performance in Kinshasa (Democratic Republic of Congo), with high diversity of HIV-1 recombinants. In 2016, 160 dried blood samples (DBS) were collected from 85 children (60 HIV−, 18 HIV+, 7 HIV-exposed) and 75 HIV+ adults (65 treated, 10 naive) at Monkole Hospital (Kinshasa). We compared viraemia with Cepheid-POC-Xpert-HIV-1VL and the non-POC-COBAS®AmpliPrep/COBAS®TaqMan®HIV-1-Testv2 in all HIV+, carrying 72.4%/7.2% HIV-1 unique/complex recombinant forms (URF/CRF). HIV-1 infection was confirmed in 14 HIV+ children by Cepheid-POC-Xpert-HIV-1Qual and in 70 HIV+ adults by both Xpert-VL and Roche-VL, identifying 8 false HIV+ diagnosis performed in DRC (4 adults, 4 children). HIV-1 was detected in 95.2% and 97.6% of 84 HIV+ samples by Xpert-VL and Roche-VL, respectively. Most (92.9%) HIV+ children presented detectable viraemia by both VL assays and 74.3% or 72.8% of 70 HIV+ adults by Xpert or Roche, respectively. Both VL assays presented high correlation (R2 = 0.89), but showing clinical relevant ≥0.5 log VL differences in 15.4% of 78 cases with VL within quantification range by both assays. This is the first study confirming the utility of Xpert HIV-1 tests for detection-quantification of complex recombinants currently circulating in Kinshasa.
机译:现场护理(POC)分子检测可在资源有限的环境中改善HIV婴儿的诊断和病毒载量(VL)定量。我们评估了具有高度多样性HIV-1重组子的金沙萨(刚果民主共和国)的POC表现。 2016年,在Monkole医院(金沙萨)从85名儿童(60名HIV-,18名HIV +,7名暴露于HIV的成年人)和75名HIV +成年人(接受治疗的65名,10名未接受过治疗)中收集了160份干血样本。我们将病毒血症与造父虫-POC-Xpert-HIV-1VL和非POC-COBAS ® AmpliPrep / COBAS ® TaqMan ® HIV-所有HIV +中的1-Testv2,带有72.4%/ 7.2%HIV-1独特/复杂重组形式(URF / CRF)。 Cepheid-POC-Xpert-HIV-1Qual在14名HIV +患儿中确认了HIV-1感染,Xpert-VL和Roche-VL均在70名HIV +患儿中确认了DRC进行了8例错误的HIV +患儿诊断(4名成人,4名儿童)。 。 Xpert-VL和Roche-VL分别在84个HIV +样本中检测到HIV-1的95.2%和97.6%。通过VL分析,大多数(92.9%)HIV +儿童表现出可检测的病毒血症,而Xpert或Roche分别在70名HIV +儿童中表现出74.3%或72.8%。两种VL测定均显示出高度相关性(R 2 = 0.89),但在这两种测定的定量范围内,在78例VL中,有15.4%的临床相关≥0.5log VL差异。这是第一项证实Xpert HIV-1检测可用于检测和定量目前在金沙萨流通的复杂重组体的实用性的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号